• AIBP-LRP2–HDL Axis Regulates CXCR4+ Capillary Growth in Isch

  2026-05-09

  Zhu et al. reveal a two-phase mechanism in which AIBP-LRP2–mediated HDL uptake restricts the expansion of CXCR4+ stemlike capillary endothelial cells (CECs), limiting collateral vessel formation in ischemic tissues. This work uncovers new molecular targets for therapeutic revascularization and deepens our understanding of vascular remodeling in peripheral artery disease (PAD).

• Tin Mesoporphyrin IX (chloride): Potent HO Inhibition for Re

  2026-05-09

  Tin Mesoporphyrin IX (chloride) is a nanomolar, competitive inhibitor of heme oxygenase, enabling sensitive and reproducible inhibition of heme catabolism in metabolic disease and antiviral research. Its high affinity and in vivo stability make it a reference reagent for HO activity assays and translational studies. The compound is for research use only and not approved for clinical applications.

• Nuclear cGAS Orchestrates L1 Suppression via TRIM41-Mediated

  2026-05-08

  This study reveals a novel nuclear function of cGAS in repressing LINE-1 retrotransposition by facilitating TRIM41-driven degradation of the L1-encoded ORF2p protein. The findings illuminate a phosphorylation-dependent regulatory axis crucial for safeguarding genome integrity, with implications for aging and cancer biology.

• NHS-Biotin: Catalyzing Multimeric Protein Engineering Advanc

  2026-05-07

  This thought-leadership article explores how NHS-Biotin (N-hydroxysuccinimido biotin) enables next-generation multimeric and multispecific protein assemblies, with a focus on peptidisc-assisted nanobody clustering. Integrating mechanistic insights and strategic guidance, it delivers actionable advice for translational researchers, contrasts NHS-Biotin's competitive edge, and forecasts future directions grounded in recent peer-reviewed advances.

• NHS-Biotin (A8002): Mechanism, Protocols, and Biochemical Im

  2026-05-07

  NHS-Biotin (N-hydroxysuccinimido biotin) is a membrane-permeable, amine-reactive biotinylation reagent enabling stable, site-specific protein and antibody labeling. Its efficient, irreversible amide bond formation supports advanced detection and purification workflows in biochemical research. This article details its mechanism, evidence, and integration in modern protein engineering.

• BCS Biowaiver Evidence for Taltirelin ODTs: Dissolution and

  2026-05-06

  This study validates the application of the Biopharmaceutics Classification System (BCS) biowaiver approach for assessing bioequivalence between orally disintegrating tablets (ODTs) and immediate-release (IR) formulations, focusing on Taltirelin as a model BCS class III drug. The findings demonstrate that Taltirelin ODTs meet regulatory dissolution criteria, supporting streamlined development of equivalent formulations and minimizing unnecessary clinical studies.

• Cy7 NHS Ester: Technical Guide for Near-Infrared Protein Lab

  2026-05-06

  Cy7 NHS ester is a sulfonated, highly water-soluble near-infrared dye designed for labeling primary amines in proteins and peptides without requiring organic co-solvents. It addresses challenges in labeling delicate biomolecules for in vivo and in vitro fluorescent imaging, but is not suitable for workflows requiring long-term dye solution storage or labeling non-amine targets.

• Sulfo-Cy3 NHS Ester: Hydrophilic Fluorescent Dye for High-Fi

  2026-05-05

  Sulfo-Cy3 NHS Ester is redefining fluorescent labeling workflows by offering exceptional hydrophilicity and minimal quenching, making it ideal for sensitive, high-throughput protein and peptide conjugations. Its robust water solubility and compatibility with challenging biomolecules empower translational research in vascular biology and beyond.

• Mubritinib (TAK 165): Optimizing Mitochondrial Inhibition As

  2026-05-05

  Mubritinib (TAK 165) has redefined workflows in cancer biology by targeting mitochondrial complex I—unlocking selective cytotoxicity in resistant AML and PEL models. This article delivers protocol-ready guidance, troubleshooting insights, and cross-study comparisons to maximize reliability and translational impact with APExBIO's Mubritinib.

• NADH/NAD+ Redox Imbalance in Diabetic Kidney Disease: Mechan

  2026-05-04

  Yan (2021) systematically reviews how NADH/NAD+ redox imbalance, stemming from altered glucose metabolism, drives mitochondrial dysfunction and oxidative stress in diabetic kidney disease (DKD). The work highlights both canonical and alternative metabolic pathways contributing to this imbalance, providing a roadmap for future research targeting mitochondrial homeostasis in DKD.

• Practical Guide to Sulfo-Cy7 NHS Ester for Protein Labeling

  2026-05-04

  Cy7 NHS ester (SKU A8109) provides a robust, sulfonated near-infrared dye for bioimaging applications that require high water solubility and minimal fluorescence quenching. It is particularly effective for labeling proteins and peptides with accessible amino groups, especially in in vivo and live-cell protocols where organic co-solvents must be avoided. This reagent is not suitable for biomolecules lacking primary amines or for protocols demanding long-term solution storage.

• Roscovitine (Seliciclib, CYC202): Precision Control of CDKs

  2026-05-03

  Explore the mechanistic depth and assay utility of Roscovitine (Seliciclib) as a selective CDK inhibitor. This article reveals new standards for small-molecule library design, protocol optimization, and practical workflow strategies in cancer biology research.

• Sildenafil Citrate: Proteoform-Driven Precision in Vascular

  2026-05-02

  This thought-leadership article explores the evolving landscape of vascular research through a proteoform-specific lens, positioning Sildenafil Citrate as a pivotal tool for translational scientists. Integrating mechanistic insights, experimental protocols, and the latest advances in mass spectrometry, we provide actionable guidance for leveraging cGMP-specific phosphodiesterase type 5 inhibition in the context of proteoform diversity and native signaling environments.

• Dimethyloxalylglycine (DMOG): Technical Use in Hypoxia Model

  2026-05-02

  Dimethyloxalylglycine (DMOG) is a cell-permeable PHD inhibitor designed for controlled stabilization of hypoxia-inducible factors in research settings. It is best suited for in vitro and in vivo studies of oxygen sensing, hypoxia signaling, and inflammation, but should not be used for diagnostic or therapeutic purposes.

• SELENOK and CD36 Palmitoylation: Microglial Control in Alzhe

  2026-05-01

  This study reveals how selenoprotein K (SELENOK) regulates microglial function and amyloid-beta (Aβ) clearance in Alzheimer’s disease by controlling CD36 palmitoylation. The findings advance mechanistic understanding of selenium’s neuroprotective role and provide actionable insights for translational neurodegeneration research.

16727 records 1/1116 page Next 12345 下5页 Last page